证券代码：600301 证券简称：华锡有色 编号：2025-048 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广西华锡有色金属股份有限公司（以下简称"公司"）第九届监事会第十七 次会议通知与相关文件于 2025 年 8 月 1 日通过电子材料和书面通知方式送达， 并于 2025 年 8 月 13 日在南宁市良庆区体强路 12 号北部湾航运中心 A 座 910 会 议室以现场会议方式召开。本次会议应出席会议的监事 4 名，实到 4 名。会议由 监事会主席陆春华先生主持。本次会议的召集和召开符合《中华人民共和国公司 法》和《公司章程》的有关规定。经与会监事认真审议，形成如下决议： 三、审议通过《关于调整广西华锡有色金属股份有限公司 2025 年度日常关 联交易预计的议案》 表决情况：4 票赞成、0 票反对、0 票弃权。 二、审议通过《关于〈广西华锡有色金属股份有限公司 2025 年半年度募集 资金存放与实际使用情况的专项报告〉的议案》 监事会对《关于〈广西华锡有色金属股份有限公司 2025 年半年度募集资金 存放与实际使用情 ...

Core Viewpoint - The company, Suzhou Xidian New Energy Electric Co., Ltd., is utilizing raised funds to increase capital in its wholly-owned subsidiary, aiming to implement investment projects effectively [1][2][6]. Fundraising Overview - The total amount raised from the initial public offering (IPO) is RMB 1,172,408,000, with a net amount of RMB 1,172,408,000 after deducting issuance costs [1][2]. - The funds are managed in a dedicated account, ensuring secure usage through a regulatory agreement with the sponsor and banks [2]. Investment Project Details - The main investment project is the expansion of the production capacity for 8 million power battery connection systems, with a total estimated investment of RMB 895.0184 million and an allocated amount of RMB 869.6652 million [2]. Capital Increase Situation - The company plans to increase the registered capital of its subsidiary, Suzhou Xidian New Energy Automotive Electronics Co., Ltd., by RMB 100 million, raising it from RMB 50 million to RMB 150 million [3][4]. Financial Data of the Subsidiary - As of the first half of 2025, the subsidiary's total assets amounted to RMB 138,078.06 million, with net assets of RMB 18,295.62 million and a net profit of RMB 3,148.29 million [5]. Impact of Capital Increase - The capital increase is intended to meet the funding needs of the investment projects, ensuring their smooth implementation and aligning with the company's development plan [5][6]. Regulatory Compliance - The decision to use raised funds for the capital increase has been approved by the company's board and is pending approval from the shareholders' meeting, complying with legal and regulatory requirements [6].

Core Points - The company intends to use its own funds to pay for part of the fundraising project expenses and subsequently replace them with the raised funds, which is aimed at improving fund utilization efficiency and overall operational management efficiency [1][4][5] Fundraising Overview - The total amount raised by the company is RMB 1,172,408,000, with a net amount of RMB 1,172,408,000 after deducting issuance costs [1] - The company has established a dedicated account for managing the raised funds and signed a regulatory agreement with the sponsor and bank to ensure the safety of fund usage [2] Investment Project Details - The main investment project is the expansion of the production capacity for 8 million power battery connection systems, with a total expected investment of RMB 895.0184 million and an allocated amount of RMB 869.6652 million from the raised funds [2] Reasons for Using Own Funds - The company needs to use its own funds for prepayments in the fundraising project due to operational convenience, particularly for the "R&D Center Construction Project," which involves various personnel costs and materials [3] Operational Process for Fund Replacement - The company will regularly summarize the amounts paid with its own funds and transfer equivalent amounts from the dedicated fundraising account to its own funds account, ensuring that the funds are used solely for the corresponding investment projects [3][4] Impact on the Company - The decision to use own funds for project payments and replace them with raised funds is expected to enhance fund utilization efficiency and reduce financial costs, aligning with the interests of the company and its shareholders [4] Approval Process - The company's board of directors approved the proposal on August 14, 2025, and it does not require submission to the shareholders' meeting for further approval [4] Sponsor's Verification Opinion - The sponsor has verified that the company's proposal to use its own funds for project payments and replace them with raised funds has been approved by the board and complies with relevant regulations, ensuring that it will not affect the normal implementation of the investment projects [4][5]

Core Viewpoint - The report details the usage and management of funds raised by Qipai Technology Co., Ltd. during its initial public offering, confirming that all funds have been utilized as promised in the prospectus and that the special account has been closed [1][2]. Fundraising Details - The total amount raised in the IPO was RMB 393,767,400, with a net amount of RMB 338,224,573.85 after deducting various fees [1]. - The funds were received on June 17, 2021, and the verification report was issued by Tianzhi International Accounting Firm on the same day [2]. Fund Usage - As of June 30, 2025, all raised funds have been fully utilized, and the special account has been closed [2][5]. - The funds were primarily used to increase the company's capital and expand related business operations, consistent with the commitments made in the prospectus [3][4]. Investment Projects - There were no changes to the actual investment projects funded by the raised capital, and the company has not transferred or replaced any investment projects [3][4]. - The company approved the use of RMB 80,665,400 to replace pre-invested funds and cover issuance costs, which was verified by Tianzhi International Accounting Firm [4]. Idle Funds Management - The company utilized up to RMB 25,000,000 of temporarily idle funds for cash management, with a rolling usage period of 12 months [4]. - As of June 30, 2025, the balance of idle funds used for purchasing financial products was RMB 0.00 [5]. Project Benefits - The benefits from the investment projects were calculated using the same methods as promised, with no projects reporting returns below 20% of the expected benefits [6]. - The R&D center expansion project could not be individually assessed for benefits but aimed to enhance overall R&D capabilities, indirectly improving company performance [6]. Comparison with Annual Reports - The actual usage of the raised funds has been consistent with the disclosures made in the company's periodic reports from 2021 to the present [6].

Core Viewpoint - The company has approved the use of its own funds and bank acceptance bills to pay for fundraising projects, with plans to replace these with raised funds later, ensuring the normal implementation of fundraising projects [1][6][7] Summary of Fundraising Situation - The company raised a total of RMB 839.4 million by issuing 60 million shares at RMB 13.99 per share, with total issuance costs amounting to RMB 79.83 million [1][2] - The funds were fully received by July 13, 2020, and have been managed in a dedicated account as per regulatory requirements [1][2] Summary of Investment Projects - As of June 30, 2025, the raw material drug production R&D project has been completed, while other fundraising projects are ongoing [2][3] - Specific projects include the Phase III clinical project for Aibond (艾诺韦林片) and the ACC008 project, with total investments of RMB 53.22 million and RMB 38.60 million respectively [3][4] Reasons for Using Own Funds - The company has used its own funds and bank acceptance bills for several reasons, including the need to pay employee salaries and taxes, which cannot be paid directly from the fundraising account [4][5] - Additionally, payments for overseas equipment and services require foreign currency, which cannot be processed through the fundraising account [4][5] Operational Process for Fund Replacement - The company will regularly compile a detailed list of payments made with its own funds and bank acceptance bills, which will be approved by the financial department [5][6] - After approval, equivalent amounts will be transferred from the fundraising account to replace the funds used [5][6] Impact on Daily Operations - The use of own funds and bank acceptance bills is expected to enhance the efficiency of fund utilization without affecting the normal operation of fundraising projects or the company's daily business [6][7] Review Procedures - The board and supervisory committee have approved the proposal to use own funds and bank acceptance bills, which does not require shareholder approval [6][7] - The proposal aligns with regulatory requirements and does not alter the intended use of the raised funds [6][7]

Core Viewpoint - The company intends to use part of its idle raised funds to temporarily supplement its working capital, with a limit of 50 million yuan, for a period not exceeding 12 months, ensuring compliance with regulatory requirements and maintaining the integrity of its investment projects [1][5][6]. Summary by Sections 1. Basic Situation of Raised Funds - The company has received approval from the China Securities Regulatory Commission for a non-public issuance of 88,008,000 shares at a price of 4.36 yuan per share, raising a total of 383,714,880 yuan, with a net amount of 376,615,860.47 yuan after deducting issuance costs [1][3]. 2. Previous Use of Idle Funds - The company previously used 50 million yuan of idle raised funds to supplement working capital, which was fully returned to the special account by August 14, 2025 [2]. 3. Investment Project Overview - The raised funds are allocated for several projects, including the acquisition of a 30% stake in Hezhong Building Materials, the construction of a PCCP production base in Henan, and a denitrification project for sintering machines [2][3][4]. 4. Current Plan for Temporary Use of Idle Funds - The company plans to use 50 million yuan of idle raised funds temporarily to meet operational needs while ensuring that the investment projects continue as planned [4][5]. 5. Board Review Process and Compliance - The board approved the use of idle funds without requiring shareholder meeting approval, confirming adherence to relevant regulations and ensuring no change in the intended use of the raised funds [5][6]. 6. Special Opinions and Sponsor's View - The sponsor, Zhongde Securities, supports the company's plan, confirming that it follows necessary legal procedures and does not harm the interests of the company or its shareholders [6].

广东科翔电子科技股份有限公司 根据中国证券监督管理委员会发布的《监管规则适用指引——发行类第 7 号》及相关规定，广东科翔电子科技股份有限公司（以下简称"本公司"）编制的 截至 2025 年 6 月 30 日《前次募集资金使用情况的专项报告》如下： 一、前次募集资金的募集及存放情况 （一）2020 年 11 月首次公开发行 A 股股票募集资金情况 经中国证券监督管理委员会"证监许可[2020]2393 号"文《关于同意广东科翔 电子科技股份有限公司首次公开发行股票注册的批复》同意注册，并经深圳证券 交易所同意，本公司由主承销商申港证券股份有限公司用网下询价配售与网上资 金申购定价发行相结合的方式发行人民币普通股(A 股)股票 4310 万股，发行价 格为每股 13.06 元。 本公司募集资金总额为 562,886,000.00 元，扣除公开发行股票发生的费用 况：扣除承销费用 39,826,839.62 元后实际资金到账 523,059,160.38 元，差额 本公司对募集资金采取了专户存储管理，前述募集资金已于 2020 年 11 月 2 日由主承销商申港证券汇入公司募集资金监管账户。公司 4 个募集资金专 ...

Core Points - The board of directors of Wangsu Technology Co., Ltd. held its 27th meeting on August 14, 2025, to review and approve several key proposals related to the company's financial performance and operational activities [1][2]. Financial Performance - The company reported a total operating income of 786.13 million yuan, representing a year-on-year increase of 7.71% [1]. - The net profit attributable to shareholders of the listed company was 372.51 million yuan, showing a year-on-year growth of 25.33% [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 261.40 million yuan, reflecting a year-on-year increase of 22.53% [1]. Board Resolutions - The board unanimously approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results [2]. - A special report on the storage and use of raised funds for the first half of 2025 was also approved [2]. - The board agreed to provide guarantees for its wholly-owned subsidiary, Shanghai Yunshu Technology Co., Ltd., for a loan application to Shanghai Bank, with a total guarantee amount not exceeding 30 million yuan [3]. - The company decided to apply for a credit limit of 30 million yuan from Ningbo Bank, with the credit being renewable within a one-year term [3].

东兴证券股份有限公司关于 青岛百洋医药股份有限公司 使用部分暂时闲置募集资金临时补充流动资金的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为青岛 百洋医药股份有限公司（以下简称"百洋医药"或"公司"）2021 年度首次公开 发行股票、2023 年度向不特定对象发行可转换公司债券持续督导的保荐机构， 根据《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》 《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等规定，对百洋医药使用部分暂时闲置募集资金 临时补充流动资金的事项进行了核查，具体核查情况如下： 由于公司首次公开发行股票募集资金净额少于《青岛百洋医药股份有限公司 首次公开发行股票并在创业板上市招股说明书》中募投项目拟投入的募集资金金 额，根据实际募集资金净额，结合各募投项目的情况，公司对募集资金投资项目 拟投入募集资金金额进行调整。 根据市场变化及公司经营需要，为提高募集资金使用效率，公司终止"现代 物流配送中心建设项目"，该项目不再实施，并将上述项目的募集资金余额 时实际剩余募集资金金额为准）调整用于新项 ...

Core Viewpoint - The company, 技源集团, is utilizing raised funds to increase capital or provide loans to its wholly-owned subsidiary, 启东技源, for the implementation of investment projects, ensuring compliance with regulatory requirements and safeguarding the interests of the company and its shareholders [1][5][6] Fundraising Overview - The company has successfully issued 50.01 million shares at a price of 10.88 RMB per share, raising a total of 544.11 million RMB, with a net amount of 479.82 million RMB after deducting issuance costs of 64.29 million RMB [1][2] - The total investment for the projects funded by the raised capital is 602.73 million RMB, with the adjusted amount for the projects being 479.82 million RMB [2] Investment Project Details - The funds will be allocated to two main projects: the expansion of the nutrition and health food production line and the establishment of a technology innovation center, both managed by the subsidiary 启东技源 [2][3] - A total of 147.31 million RMB from the raised funds will be used for these projects, with the loan terms being flexible based on the actual needs of the projects [2][5] Subsidiary Information - 启东技源 is a wholly-owned subsidiary of the company, with a registered capital of 212.65 million RMB and a business scope that includes health food production and sales [3][4] - Recent financial data shows total assets of 344.98 million RMB, total liabilities of 56.37 million RMB, and net assets of 288.61 million RMB, with a revenue of 240.33 million RMB and a net profit of 32.78 million RMB [4] Impact on the Company - The use of raised funds for the subsidiary is aligned with the company's long-term strategic goals and ensures the smooth implementation of investment projects, maintaining control over financial risks [5][6] - The company has established a four-party supervision agreement to ensure the safe management of the raised funds, complying with relevant regulations [5][6] Approval Process - The board of directors and the supervisory board have approved the use of raised funds for the subsidiary, confirming that the process adheres to necessary approval protocols without requiring shareholder meeting approval [5][6] - The supervisory board has expressed that the funding allocation does not alter the intended use of the raised funds and does not harm the interests of the company or its shareholders [5][6]